N/A N=120 Diabetes Education With Real-time Continuous Glucose Monitoring
Diabetes Type 2
Primary: Hemoglobin A1C — -2.3; -1.5 percent change in A1C
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=64 A Study in Healthy People to Compare How 2 Different High Dose Formulations of BI 1015550 Are Taken up in the Body
Healthy
Primary: Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 2275.77; 2166.70…
Phase 1 N=18 A Study in Healthy People to Test How BI 1015550 is Taken up in the Body When Given With or Without Food
Healthy
Primary: Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point) (AUC0-tz) — 2225.20; 2563.65…
Phase 2 N=70 Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma
Resectable Esophageal Squamous Cell Carcinoma
Primary: Pathological Complete Response (pCR) Rate — 30.0; 34.4 percentage of participants
N/A N=1 Prostate Resection After Microwave Ablation (PRAMA)
Prostate Carcinoma
Primary: The Area of the Transperineal Targeted Microwave Ablation (TMA) Induced Tissue Death Assessed by Triphenyltetrazolium Chloride (TTC) Staining
Phase 1 N=26 A Study to Test How BI 1015550 is Taken up in the Blood of People With and Without Kidney Problems
Renal Insufficiency · Healthy
Primary: Area Under the Concentration-time Curve of R-BI 1015550 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 3347.73; 2590.32…
Phase 3 N=895 Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)
Advanced/Metastatic Gastroesophageal Adenocarcinoma
Primary: Part 1: Number of Participants With Dose Limiting Toxicities (DLTs) — 2 Participants
N/A N=60 Care Partner Assisted Intervention to Improve Oral Health of Individuals With Mild Dementia
Mild Dementia
Primary: Plaque Index — 0.55; 0.41; 0.48 Proportion of sites with plaque deposits — p=0.939
Phase 2 N=12 A Study of Pegcetacoplan for Patients With Transplant-associated Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplantation
Transplant-Associated Thrombotic Microangiopathy
Primary: Pegcetacoplan Pharmacokinetic (PK) Parameter Area Under the Curve Limited to the End of Dosing Interval (AUC0-tau) — 14934.65; 20089.79; 36208.37 µg*h/mL
N/A N=42 Feasibility of Remote Tai Chi
PTSD · Pain, Chronic
Primary: Participant Satisfaction Post Treatment With Interventions Being Tested — 3.61; 3.40 score on a scale
Phase 3 N=9,902 A Study of S-268019 for the Prevention of COVID-19
SARS-CoV-2
Primary: Number of Participants With First Occurrence of SARS-CoV-2 Reverse Transcription Polymerase Chain Reaction (RT-PCR)-Positive Symptomatic COVID-19 With Onset at Least 14…
Phase 2 N=155 A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever
Salmonella Infections
Primary: Stage 1: Number of Participants With Any Solicited Administration Site Events After the First Study Intervention Administration — 1; 0; 0; 0 Participants
Phase 1 N=16 This Study in Healthy Men Tests How Itraconazole Influences the Amount of BI 1015550 in the Blood
Healthy
Primary: Area Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 to 119 Hours — 2073.40; 933.44 nanomole (nmol)*h/Litre (L)
Phase 4 N=186 Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge Study
Hyperkalaemia · Chronic Kidney Disease
Primary: Occurrence (Yes/No) of NK (K+ Between 3.5 and 5.0 mmol/L, Inclusive) at 180 Days Post-discharge — 21; 25; 47; 44 Number of participants — p=0.558
Phase 1 N=8 A Study in Healthy Men to Test How BI 1015550 is Taken up and Handled by the Body
Healthy
Primary: Dose Normalized Area Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-inf) — 118.27; 161.69…